Lysis of murine B lymphoma cells by transgenic phagocytes via a human FcγRIxmurine MHC class II bispecific antibody

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 166-170

  Heijnen, Ingmar A F M ^a   Glennie, Martin J ^b   Van De Winkel, Jan G J ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c Department of Immunology ^*  (Netherlands)

Author keywords

B cell lymphoma; Bispecific antibody; CD64; Fc receptor; Transgenic

Indexed keywords

BISPECIFIC ANTIBODY; FC RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY;

ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; NEUTROPHIL; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TRANSGENIC MOUSE; TUMOR CELL DESTRUCTION;

ANIMALS; ANTIBODIES, BISPECIFIC; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PHAGOCYTES; PHAGOCYTOSIS; RECEPTORS, FC;

EID: 0030772183     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050424     Document Type: Article

References (21)

1. Bridges SH, Kruisbeek AM, Longo DL (1987) Selective in vivo antitumour effects of monoclonal anti-1-A antibody on B cell lymphoma. J Immunol 139:4242
2. Curnow RT, Pfister DG, Deo Y, Motzer RJ, Winston C, Keeperman KL, Malone T (1997) A phase I trial of bispecific antibody (bsAb) MDX447 without and with granulocyte colony-stimulating factor (G-CSF) in patients with adult solid tumours. Proc Am Soc Clin Oncol 16:438a
3. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF (1994) Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 73:1425
4. Deo YM, Graziano RF, Repp R, Winkel JGJ van de (1997) Clinical significance of IgG receptors and FcγR-directed immunotherapies. Immunol Today 18:127
5. Elsässer D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, Winkel JGJ van de, Stevenson GT, Glennie MJ, Gramatzki M (1996) HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 87:3803
6. Gill I, Agah R, Hu E, Mazamder A (1989) Synergistic antitumour effects of interleukin 2 and the monoclonal antibody Lym-1 against human Burkitt lymphoma cells in vitro and in vivo. Cancer Res 49:5377
7. 3 antibody derivates. In: Gallagher G, Rees RC, Reynolds CW (eds) Tumour immunobiology, a practical approach. IRL Press at Oxford University Press, London, p 225
8. Goldstein J, Graziano RF, Sundarapandiyan K, Somasundaram C, Deo YM (1997) Cytolytic and cytostatic properties of an antihuman FcγRI (CD64) x epidermal growth factor bispecific fusion protein. J Immunol 158:872
9. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863
10. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW (1989) Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J Immunol 143:1650
11. Heijnen IAFM, Vugt MJ van, Fanger NA, Graziano RF, de Wit TPM, Hofhuis FMA, Guyre PM, Capel PJA, Verbeek JS, Winkel JGJ van de (1996) Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 97:331
12. Heijnen IAFM, Rijks LJM, Schiel A, Stockmeyer B, van Ojik HH, Dechant M, Valerius T, Keler T, Tutt AL, Glennie MJ, Royen EA van, Capel PJA, Winkel JGJ van de (1997) Generation of HER-2/ neu-specific cytotoxic neutrophils: efficient arming of PMN by combined administration of G-CSF and FcγRI bispecific antibodies. J Immunol (in press)
13. Jones B, Tite JP, Janeway CA Jr (1986) Different phenotypic variants of the mouse B cell tumour A20/2J are selected by antigen- and mitogen-triggered cytotoxicity of L3T4-positive. IA-restricted T cell clones. J Immunol 136:348
14. Kerst JM, Winkel JGJ van de, Evans AH, Haas M de, Slaper-Cortenbach ICM, de Wit TPM, Borne AEGKr von dem, Schoot CE van der, Oers RHJ van (1993) Granulocyte colony-stimulating factor induces hFcγRI (CD64 antigen)-positive neutrophils via an effect on myeloid precursor cells. Blood 81:1457
15. Martino G, Anastasi J, Feng J, Mc Shan C, DeGroot L, Quintans J, Grimaldi LME (1993) The fate of human peripheral blood lymphocytes after transplantation into SCID mice. Eur J Immunol 23:1023
16. Marx JL (1983) Suppressing autoimmunity in mice. Science 221:843
17. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trumper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M (1994) Cure of xenografted human tumours by bispecific monoclonal antibodies and human T cells. Science 264:833
18. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV (1994) FcR chain deletion results in pleiotrophic effector cell defects. Cell 76:519
19. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano RF, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Morley TL, Arvizu C, Fanger MW (1995) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that over-expresses the proto-oncogene HER-2/neu. J Clin Oncol 13:2281
20. Vugt MJ van, Heijnen IAFM, Capel PJA, Park SY, Ra C, Saito T, Verbeek JS, Winkel JGJ van de (1996) FcR γ-chain is essential for both surface expression and function of human FcγRI (CD64) in vivo. Blood 87:3593
21. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, De Palazzo IG (1993) A human tumour xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 53:94